Vaginal microbicides: where are we and where are we going?

Area of Science:

• Reproductive Health
• Infectious Diseases
• Biomedical Science

Background:

• The HIV epidemic necessitates safe and effective prevention methods controllable by women, such as vaginal microbicides.
• Previous microbicide trials, like nonoxynol-9, highlighted safety concerns and the need for rigorous standards.
• Acquisition of HIV is often exacerbated by co-existing sexually transmitted infections.

Purpose of the Study:

• To review the current landscape of vaginal microbicide development for HIV prevention.
• To address the challenges and opportunities presented by recent clinical trial outcomes.
• To emphasize the critical need for continued research and development of novel microbicides.

Main Methods:

• Review of preclinical and clinical trial data for vaginal microbicides.
• Analysis of safety standards, including immune markers and colposcopy.
• Categorization of current microbicide candidates based on their mechanisms of action.

Main Results:

• Recent Phase IIb/III trials have yielded disappointing results, underscoring development challenges.
• Existing safety standards require further refinement, particularly regarding immune markers.
• Current microbicides are categorized into defense enhancers, surfactants, entry inhibitors, and reverse transcriptase inhibitors.

Conclusions:

• Continued research into novel microbicides and improved preclinical models/biomarkers is crucial.
• Establishing robust safety and efficacy standards remains a priority.
• Partner acceptance is a vital, often underestimated, factor for successful microbicide implementation.